Published in Cell Death Differ on April 28, 2006
Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol (2010) 8.55
The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev (2009) 3.23
Wallerian degeneration, wld(s), and nmnat. Annu Rev Neurosci (2010) 3.22
Drosophila NMNAT maintains neural integrity independent of its NAD synthesis activity. PLoS Biol (2006) 2.70
Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol (2010) 2.22
Nicotinamide mononucleotide adenylyl transferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide. J Neurosci (2009) 2.15
NAD synthase NMNAT acts as a chaperone to protect against neurodegeneration. Nature (2008) 2.01
Wld S requires Nmnat1 enzymatic activity and N16-VCP interactions to suppress Wallerian degeneration. J Cell Biol (2009) 1.98
Mutations in NMNAT1 cause Leber congenital amaurosis and identify a new disease pathway for retinal degeneration. Nat Genet (2012) 1.96
Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters. J Biol Chem (2009) 1.70
Transgenic mice expressing the Nmnat1 protein manifest robust delay in axonal degeneration in vivo. J Neurosci (2009) 1.69
Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nat Rev Neurosci (2014) 1.66
Activation of SIRT3 by the NAD⁺ precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab (2014) 1.66
Nmnat delays axonal degeneration caused by mitochondrial and oxidative stress. J Neurosci (2008) 1.54
Wld S protein requires Nmnat activity and a short N-terminal sequence to protect axons in mice. J Cell Biol (2009) 1.53
Wallerian degeneration: the innate-immune response to traumatic nerve injury. J Neuroinflammation (2011) 1.41
SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions. Biochim Biophys Acta (2009) 1.41
Death Receptor 6 Promotes Wallerian Degeneration in Peripheral Axons. Curr Biol (2017) 1.39
Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene. Mol Cell Proteomics (2007) 1.35
Wld(S), Nmnats and axon degeneration--progress in the past two decades. Protein Cell (2010) 1.21
Isoform-specific targeting and interaction domains in human nicotinamide mononucleotide adenylyltransferases. J Biol Chem (2010) 1.15
Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol (2011) 1.14
Subcellular localization determines the stability and axon protective capacity of axon survival factor Nmnat2. PLoS Biol (2013) 1.03
Modified cell cycle status in a mouse model of altered neuronal vulnerability (slow Wallerian degeneration; Wlds). Genome Biol (2008) 1.02
Mislocalization of neuronal mitochondria reveals regulation of Wallerian degeneration and NMNAT/WLD(S)-mediated axon protection independent of axonal mitochondria. Hum Mol Genet (2013) 1.01
A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration. Cell Death Differ (2014) 1.01
Wallerian-like degeneration of central neurons after synchronized and geometrically registered mass axotomy in a three-compartmental microfluidic chip. Neurotox Res (2010) 1.00
Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitotoxic-necrotic cell death. Proc Natl Acad Sci U S A (2011) 0.99
The back and forth of axonal injury and repair after stroke. Curr Opin Neurol (2014) 0.94
NAD and axon degeneration: from the Wlds gene to neurochemistry. Cell Adh Migr (2009) 0.94
WldS but not Nmnat1 protects dopaminergic neurites from MPP+ neurotoxicity. Mol Neurodegener (2012) 0.89
Molecular mechanisms of retinal ganglion cell degeneration in glaucoma and future prospects for cell body and axonal protection. Front Cell Neurosci (2013) 0.88
Targeting anti-inflammatory treatment can ameliorate injury-induced neuropathic pain. PLoS One (2013) 0.88
Synaptic protection in the brain of WldS mice occurs independently of age but is sensitive to gene-dose. PLoS One (2010) 0.87
Deletions within its subcellular targeting domain enhance the axon protective capacity of Nmnat2 in vivo. Sci Rep (2013) 0.87
NMNATs, evolutionarily conserved neuronal maintenance factors. Trends Neurosci (2013) 0.87
Protection of mouse retinal ganglion cell axons and soma from glaucomatous and ischemic injury by cytoplasmic overexpression of Nmnat1. Invest Ophthalmol Vis Sci (2013) 0.86
Preserve and protect: maintaining axons within functional circuits. Trends Neurosci (2014) 0.86
Signaling mechanisms regulating Wallerian degeneration. Curr Opin Neurobiol (2014) 0.85
The neuroimmunology of degeneration and regeneration in the peripheral nervous system. Neuroscience (2014) 0.85
Sirt1's complex roles in neuroprotection. Cell Mol Neurobiol (2009) 0.84
Chemical genetic-mediated spatial regulation of protein expression in neurons reveals an axonal function for wld(s). Chem Biol (2012) 0.83
Molecular chaperones protect against JNK- and Nmnat-regulated axon degeneration in Drosophila. J Cell Sci (2012) 0.83
Novel compound heterozygous NMNAT1 variants associated with Leber congenital amaurosis. Mol Vis (2014) 0.82
Axonal trafficking of NMNAT2 and its roles in axon growth and survival in vivo. Bioarchitecture (2013) 0.80
The purine nucleosides adenosine and guanosine delay axonal degeneration in vitro. J Neurochem (2009) 0.79
Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. Pharmacogenomics (2009) 0.78
Mitochondrial dysfunction induced by heat stress in cultured rat CNS neurons. J Neurophysiol (2012) 0.78
Impact of Genetic Reduction of NMNAT2 on Chemotherapy-Induced Losses in Cell Viability In Vitro and Peripheral Neuropathy In Vivo. PLoS One (2016) 0.76
Metabolic Vulnerability in the Neurodegenerative Disease Glaucoma. Front Neurosci (2017) 0.75
UBE4B: a promising regulatory molecule in neuronal death and survival. Int J Mol Sci (2012) 0.75
KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes Dev (1996) 5.68
What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable? Br J Cancer (2009) 4.31
Visualization of Mad2 dynamics at kinetochores, along spindle fibers, and at spindle poles in living cells. J Cell Biol (2000) 4.26
Cancer survival in England and Wales at the end of the 20th century. Br J Cancer (2008) 4.18
Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci (2001) 4.10
Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol (2005) 4.07
How many deaths have been avoided through improvements in cancer survival? BMJ (2000) 3.68
Excess mortality in England and Wales, and in Greater London, during the 1995 heatwave. J Epidemiol Community Health (1998) 3.67
Trends in cancer incidence and mortality. IARC Sci Publ (1993) 3.19
The completeness of cancer registration in England: an assessment from the Oxford-FPA contraceptive study. Br J Cancer (1988) 3.07
Integral membrane protein located in the apical complex of Plasmodium falciparum. Mol Cell Biol (1989) 2.96
The completeness of cancer registration in follow-up studies--a cautionary note. Br J Cancer (1987) 2.66
Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet (1991) 2.60
Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci U S A (2000) 2.58
Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol (1992) 2.52
Deprivation, stage at diagnosis and cancer survival. Int J Cancer (1995) 2.50
Structure of the Mad2 spindle assembly checkpoint protein and its interaction with Cdc20. Nat Struct Biol (2000) 2.49
A Ufd2/D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian degeneration (WldS) mouse. Proc Natl Acad Sci U S A (2000) 2.40
Deprivation and survival from breast cancer. Br J Cancer (1995) 2.27
Prostitutes, prostitution and STD/HIV transmission in mainland China. Soc Sci Med (1996) 2.26
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology (2004) 2.23
Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol (1996) 2.22
Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol (1994) 2.21
Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes (1997) 2.19
Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol (1993) 2.09
Socioeconomic inequalities in cancer survival in England after the NHS cancer plan. Br J Cancer (2010) 2.07
Differential diagnosis of acute flaccid paralysis and its role in poliomyelitis surveillance. Epidemiol Rev (2000) 2.06
Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst (1985) 2.00
Axotomy-induced axonal degeneration is mediated by calcium influx through ion-specific channels. J Neurosci (1995) 1.88
End-of-life decision-making in respiratory intermediate care units: a European survey. Eur Respir J (2007) 1.84
Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. Eur J Cancer (2003) 1.79
Regulation of glutamine synthetase adenylylation and deadenylylation by the enzymatic uridylylation and deuridylylation of the PII regulatory protein. Arch Biochem Biophys (1973) 1.78
Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer (2001) 1.76
Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. Science (1996) 1.76
New VAPB deletion variant and exclusion of VAPB mutations in familial ALS. Neurology (2008) 1.76
Completeness of cancer registration: a new method for routine use. Br J Cancer (2000) 1.75
PANNOTATOR: an automated tool for annotation of pan-genomes. Genet Mol Res (2013) 1.74
'Cure' from breast cancer among two populations of women followed for 23 years after diagnosis. Ann Oncol (2009) 1.73
Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann Neurol (1993) 1.73
Changes over time in socioeconomic inequalities in breast and rectal cancer survival in England and Wales during a 32-year period (1973-2004): the potential role of health care. Ann Oncol (2011) 1.72
Further studies on the isolation and charcterization of parathyroid polypeptides. Biochemistry (1966) 1.72
Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS. Neurology (2007) 1.68
MAD2B is an inhibitor of the anaphase-promoting complex. Genes Dev (2001) 1.67
Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res (1988) 1.66
Choice of geographic unit influences socioeconomic inequalities in breast cancer survival. Br J Cancer (2005) 1.66
Levels of interleukin-1 beta, -8, and -10 and RANTES in gingival crevicular fluid and cell populations in adult periodontitis patients and the effect of periodontal treatment. J Periodontol (2000) 1.64
Plasmodium falciparum: two antigens of similar size are located in different compartments of the rhoptry. Exp Parasitol (1990) 1.63
Toward a comparison of survival in American and European cancer patients. Cancer (2000) 1.63
RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res (1998) 1.62
Molecular variation in a novel polymorphic antigen associated with Plasmodium falciparum merozoites. Mol Biochem Parasitol (1994) 1.60
Overexpression of Bcl-X(L) inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res (1997) 1.60
Cytokine expression of macrophages in HIV-1-associated vacuolar myelopathy. Neurology (1993) 1.59
Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J Biol Chem (2000) 1.58
Spectroscopic characterization of mineralogy and its diversity across Vesta. Science (2012) 1.57
A longitudinal analysis of nursing home outcomes. Health Serv Res (1998) 1.56
Phosphorylation and modulation of a kainate receptor (GluR6) by cAMP-dependent protein kinase. Science (1993) 1.55
Adherence of Vibrio cholerae to cultured differentiated human intestinal cells: an in vitro colonization model. Infect Immun (1997) 1.55
Variable progression of HIV-associated dementia. Neurology (1998) 1.54
Genetic basis of hemolytic anemia caused by pyrimidine 5' nucleotidase deficiency. Blood (2001) 1.52
Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol (1999) 1.50
Pesticides in Portuguese surface and ground waters. Water Res (2003) 1.50
Cancer information under threat: the case for legislation. Ann Oncol (2001) 1.49
Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells. Eur J Immunol (1988) 1.46
Neurologic prognosis of cytomegalovirus polyradiculomyelopathy in AIDS. Neurology (1993) 1.45
Multileaf collimator interleaf transmission. Med Phys (1999) 1.44
A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain. Infect Immun (1997) 1.44
Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. Br J Cancer (2013) 1.42
Inter- and intraexaminer reliability of nerve conduction measurements in patients with diabetic neuropathy. Neurology (1994) 1.42
Survival from adult leukaemia in England and Wales up to 2001. Br J Cancer (2008) 1.41
Survival of women with breast cancer in Europe: variation with age, year of diagnosis and country. The EUROCARE Working Group. Int J Cancer (1998) 1.41
Three-dimensional analysis of the cranio-cervico-mandibular complex during piano performance. Med Probl Perform Art (2014) 1.40
[Is the borderline personality disorder a complex post-traumatic stress disorder? - The state of research]. Nervenarzt (2002) 1.39
Mortality from dementia in occupations at risk of exposure to bovine spongiform encephalopathy: analysis of death registrations. BMJ (1999) 1.38
Correction of long term joint contractures of the hand by distraction. A case report. Br J Plast Surg (2005) 1.38
[How to evaluate scientific articles proposed for publication?]. Med Clin (Barc) (1991) 1.38
Trends in biliary tract cancer. Rev Epidemiol Sante Publique (1993) 1.38
Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer (1987) 1.37
Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. Gut (2005) 1.32
The Escherichia coli NadR regulator is endowed with nicotinamide mononucleotide adenylyltransferase activity. J Bacteriol (1999) 1.32
Revascularization in the rabbit hindlimb: dissociation between capillary sprouting and arteriogenesis. Cardiovasc Res (2001) 1.31
Requirement for alpha-CaMKII in experience-dependent plasticity of the barrel cortex. Science (1996) 1.31
Preliminary assessment of the safety and immunogenicity of a new CTXPhi-negative, hemagglutinin/protease-defective El Tor strain as a cholera vaccine candidate. Infect Immun (1999) 1.31
Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br J Cancer (2009) 1.30
Reconstruction of the proteolytic pathway for use of beta-casein by Lactococcus lactis. Mol Microbiol (1998) 1.30
Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence. Curr Top Microbiol Immunol (1995) 1.29
Molecular cloning, chromosomal localization, tissue mRNA levels, bacterial expression, and enzymatic properties of human NMN adenylyltransferase. J Biol Chem (2001) 1.28
Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy. J Neuropathol Exp Neurol (2000) 1.28
Hybrids between rat lymphoma and mouse T cells with inducible cytolytic activity. Nature (1982) 1.28
Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst (1987) 1.28
DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity. Proc Natl Acad Sci U S A (1997) 1.27
Trends in breast cancer incidence, survival, and mortality. Lancet (2000) 1.27
Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis. Am J Med Genet B Neuropsychiatr Genet (2011) 1.26
Opinion: why the variation in breast cancer survival in Europe? Breast Cancer Res (1999) 1.26
Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia (1999) 1.25
The WldS protein protects against axonal degeneration: a model of gene therapy for peripheral neuropathy. Ann Neurol (2001) 1.25